Callao, Peru Clinical Trials

A listing of Callao, Peru clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 99 clinical trials
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer

This is a Global Study of Neoadjuvant-Adjuvant Durvalumab or Placebo and FLOT Chemotherapy Followed by Adjuvant Durvalumab or Placebo in Patients with Resectable Gastric and Gastroesophageal Cancer (GC/GEJC) (MATTERHORN).

immunoglobulin
cancer
oxaliplatin
adenocarcinoma
monoclonal antibodies
Research Site
 (1.7 away) Contact site
  • 0 views
  • 15 Sep, 2021
  • +153 other locations
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is nave to BCG treatment (Cohort B). The primary hypothesis …

Hospital Militar Central [Lima, Peru] ( Site 0604)
 (5.4 away) Contact site
  • 108 views
  • 23 Sep, 2021
  • +141 other locations
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

mammogram
cancer
formalin-fixed paraffin-embedded
triple-negative breast cancer
paclitaxel
Research Site
 (6.9 away) Contact site
  • 1387 views
  • 26 Aug, 2021
  • +309 other locations
Evaluation of Efficacy and Safety of Pamrevlumab in Patients With Idiopathic Pulmonary Fibrosis

This is a Phase 3 trial to evaluate the efficacy and safety of 30 mg/kg intravenous (IV) infusions of pamrevlumab administered every 3 weeks as compared to placebo in subjects with Idiopathic Pulmonary Fibrosis

idiopathic pulmonary fibrosis
diffusion capacity of the lung for carbon monoxide
pirfenidone
carbon monoxide
nintedanib
Clinica Providencia
 (2.8 away) Contact site
  • 349 views
  • 23 Sep, 2021
  • +227 other locations
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Ovarian Cancer or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy

Oncosalud
 (7.9 away) Contact site
  • 5 views
  • 28 Aug, 2021
  • +174 other locations
A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer

Study MO39874 is an open-label, phase IIIb, single arm, multicenter study conducted in participants with unresectable locally advanced or metastatic PD-L1-positive Triple-Negative Breast Cancer (TNBC) who have not received chemotherapy for their unresectable locally advanced or metastatic disease.

breast adenocarcinoma
mammogram
cancer
pd-l1
metastasis
Hospital Central Fap Juan Benavides Dorich; Oncology
 (3.9 away) Contact site
  • 147 views
  • 23 Sep, 2021
  • +163 other locations
Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

The purpose of this extension study is to establish efficacy and safety of ligelizumab. This will be assessed in adult and adolescent chronic spontaneous urticaria (CSU) patients who have completed a preceding ligelizumab study and have relapsed, following treatment in these preceding studies, despite standard of care H1-antihistamine (H1-AH) treatment. …

urticaria
antihistamines
ligelizumab
Novartis Investigative Site
 (9.9 away) Contact site
  • 1 views
  • 29 Aug, 2021
  • +229 other locations
Doravirine/Islatravir (DOR/ISL) in Heavily Treatment-Experienced (HTE) Participants for Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-019)

This is a 2-part, phase 3 clinical study evaluating the antiretroviral activity and safety/tolerability of islatravir (ISL), doravirine (DOR), and a fixed dose combination (FDC) of DOR/ISL (also known as MK-8591A) in heavily treatment-experienced (HTE) participants with human immunodeficiency virus type 1 (HIV-1) infection. It is hypothesized that the percentage …

Policlinico Universidad Nacional Mayor de San Marcos ( Site 4501)
 (3.7 away) Contact site
  • 118 views
  • 22 Sep, 2021
  • +102 other locations
Randomized Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia

Phase II & Phase III: This is a pragmatic, adaptive, randomized, multicenter phase II/III study evaluating IFX-1 for the treatment of COVID-19 related severe pneumonia. The study consists of two parts: Phase II, an open-label, randomized, 2-arm phase evaluating best supportive care (BSC) + IFX-1 (Arm A) and BSC alone …

pneumonia
SARS
University of Peru
 (5.6 away) Contact site
  • 57 views
  • 08 Sep, 2021
  • +41 other locations
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

This is a study of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) as a first line intervention in a PD-L1 selected population with participants with recurrent or metastatic head and neck squamous cell carcinoma. Hypotheses include: Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response …

metastatic head and neck squamous cell carcinoma
mk-3475
cancer
pembrolizumab
measurable disease
Hospital Nacional Arzobispo Loayza ( Site 0703)
 (4.9 away) Contact site
  • 15 views
  • 22 Sep, 2021
  • +150 other locations